March 25, 2008
SymBio Pharmaceuticals Limited.
Fuminori Yoshida
Representative Director, President and Chief Executive Officer

The U.S. Food and Drug Administration (FDA) has approved New Drug
Application for TREANDA® (bendamustine HCl)

We will inform of the release article that the U.S. Food and Drug Administration (FDA) has
approved TREANDA® (bendamustine hydrochloride) for Injection for the treatment of patientswith chronic lymphocytic leukemia. Please refer to the attached paper excerpt article.
It is our pleasure to announce that this approval by FDA, to become a driving force for SymBio
Pharmaceuticals in the acceleration of its research and business development in Japan and other
Asian countries. We also see this event serving as a firm guidance for SymBio Pharmaceuticals inits target to complete the final clinical trial for the drug in the first quarter of 2008.

Contact:SymBio Pharmaceuticals Limited.
Osamu Ogawa
Board Director, Senior Corporate Officer, Research & Development,
Tel: +081(0)3 5472 1123
E-mail: Please send your inquiry through “INQUIRY” in our homepage
URL:http://www.symbiosis.co.jp

News Release

Cephalon Receives FDA Approval for TREANDA® (bendamustine HDl), a Novel
Chemotherapy for Chronic Lymphocytic Leukemia. First New Agent for CLL Patients
Approved by the U.S. Food and Drug Administration (FDA) Since 2001

FRAZER, Pa.-March 20, 2008
Cephalon, Inc. (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration(FDA) has approved TREANDA® (bendamustine hydrochloride) for Injection for the treatment ofpatients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrowdisease. The American Cancer Society estimates that more than 15,000 new cases of this raredisease will be diagnosed in the United States this year. The TREANDA® application as a CLL
treatment received priority review from the FDA and was approved within six months of theSeptember 2007 submission. Cephalon anticipates that TREANDA® will be available tophysicians and patients as a CLL treatment in the United States in April 2008.

"TREANDA® is an important new treatment for patients with chronic lymphocytic leukemia, andthis first-cycle approval by FDA represents a significant milestone in the growth of our oncology
business," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory
Operations. "With a strong pipeline of near- and longer-term opportunities, Cephalon Oncology ispoised to deliver therapies that target both hematologic cancers and solid tumors for patients inneed of new options."

Dr. Bruce Cheson, Professor of Medicine at Georgetown University Hospital, Washington, D.C.,
stated, "Patients with chronic lymphocytic leukemia can often live normal lives for many years
because of treatments that control the disease over the long-term. TREANDA® is an effective newoption that offers a delay in disease progression, an important goal for patients with chronic
lymphocytic leukemia."

In a randomized, international, multicenter, open-label pivotal study of 301 treatment-naive
patients with CLL, those who received TREANDA® had better clinical outcomes compared topatients treated with chlorambucil, an FDA-approved chemotherapy for patients with CLL.
Specifically, TREANDA® patients had a significantly higher overall response (59 percent ofpatients responded to TREANDA® and 26 percent of patients responded to chlorambucil; p <0.0001). Patients who received TREANDA® also had a higher complete response rate than thosetreated with chlorambucil (8 percent vs. <1 percent), which means that after treatment withTREANDA®, some patients had no signs of disease in their blood.

Importantly, TREANDA® patients also had a significantly longer progression-free survival (18months vs. 6 months; Hazard Ratio = 0.27; p < 0.0001), meaning the disease did not get worse fora significant period of time. The response to TREANDA® lasted longer (duration of response) thanin patients who received chlorambucil (19 months vs. 7 months). The most common adverse
events in the trial were myelosuppression, fever, nausea, and vomiting.
TREANDA® has been granted orphan drug status by the FDA for the treatment of CLL. The
orphan drug designation will provide marketing exclusivity in this indication until March 2015.

[Company Profile]
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals’ focus is on oncology/hematology and autoimmune disease therapies.
Established in March 2005 by Fuminori Yoshida, who previously served as both Corporate VicePresident of Amgen Inc. and president of Amgen Japan, SymBio Pharmaceuticals’ underlying
corporate philosophy is “delivering hope to patients in need,” and the company aims to address
unmet medical needs of patients in Japan by cultivating a mutually beneficial or symbiotic
relationship among physicians, scientists, regulatory agencies, and investors.
SymBio Pharmaceuticals core philosophy is that profitability and socially responsibility as apharmaceutical enterprise can go hand in hand, and need not be mutually exclusive.